Furthermore, kinetic analyses indicated that compounds 1 and 13 inhibited PTP1B in a noncompetitive manner; therefore, they may be potential lead compounds in the development of anti-obesity and -diabetic agents. Here, PTPN1 is linked to obesity due to melanocortin 4 receptor deficiency.